Hexanoate

Hexanoate

SCHEMBL2098722

CCCCCC(=O)O.O=C1CCC(=O)N1O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.59
GPR84 Q9NQS5 7/20 0.57
PPARG P37231 7/20 0.57
PPARD Q03181 7/20 0.57
PPARA Q07869 7/20 0.57
HDAC11 Q96DB2 5/20 0.57
TSHR P16473 4/20 0.57
PTPN1 P18031 3/20 0.57
FABP4 P15090 3/20 0.57
ALDH1A1 P00352 2/20 0.57
TLR2 O60603 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
KMT2A Q03164 2/20 0.57
ALOX15 P16050 2/20 0.57
HSD17B10 Q99714 2/20 0.57
SLC22A6 Q4U2R8 1/20 0.57
SLC22A8 Q8TCC7 1/20 0.57
MEN1 O00255 1/20 0.57
ESR1 P03372 1/20 0.57
PDE4A P27815 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Myristic Acid SCHEMBL3299115 0.98 GPR84 (0.61) AKR1B1GPR84PPARGPPARDPPARA
Palmitic Acid SCHEMBL1815959 0.98 GPR84 (0.61) AKR1B1GPR84PPARGPPARDPPARA
Stearic Acid SCHEMBL4612415 0.98 GPR84 (0.61) AKR1B1GPR84PPARGPPARDPPARA
Valeric Acid SCHEMBL29098873 0.94 AKR1B1 (0.50) AKR1B1GPR84PPARGPPARDPPARA
Adipic Acid SCHEMBL29427201 0.90 LMNA (0.50) AKR1B1GPR84PPARGPPARDPPARA
Adipic Acid SCHEMBL906129 0.90 LMNA (0.50) AKR1B1GPR84PPARGPPARDPPARA
Oleic Acid SCHEMBL28630252 0.89 PPARG (0.68) PPARGPPARDPPARATSHRPTPN1
Azelaic Acid SCHEMBL28918234 0.88 TSHR (0.52) GPR84PPARGPPARDPPARAHDAC11
Glutarate SCHEMBL9485824 0.86 SLC22A6 (0.50) GPR84HDAC11TSHRKMT2ASLC22A6
Glutarate SCHEMBL28487046 0.86 SLC22A6 (0.50) GPR84HDAC11TSHRKMT2ASLC22A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105477641-B Biosynthetic proline/alanine random coil polypeptides and uses thereof XL-蛋白有限责任公司 2021-03-23 CN disclosed
EP-2106812-B1 Methods of Making and Using Surfactant Polymers NANOMIMETICS INC (US) 2016-01-13 EP disclosed
US-9125969-B2 Methods of making and using surfactant polymers NANOMIMETICS, INC. (US) 2015-09-08 US disclosed
US-9012413-B2 FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof SANOFI (FR) 2015-04-21 US disclosed
US-20120245288-A1 METHODS OF MAKING AND USING SURFACTANT POLYMERS NANOMIMETICS, INC. (US) 2012-09-27 US disclosed
US-20120214754-A1 FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-08-23 US disclosed
US-8163302-B2 Methods of making and using surfactant polymers NANOMIMETICS, INC. (US) 2012-04-24 US disclosed
EP-2106812-A2 Methods of Making and Using Surfactant Polymers NanoMimetics, Inc. (US) 2009-10-07 EP disclosed
US-7544774-B2 Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2009-06-09 US disclosed
US-20080262614-A1 METHODS OF MAKING AND USING SURFACTANT POLYMERS NANOMIMETICS, INC. (US) 2008-10-23 US disclosed
EP-1073682-B1 HEPARANASE SPECIFIC MOLECULAR PROBES AND THEIR USE IN RESEARCH AND MEDICAL APPLICATIONS INSIGHT BIOPHARMACEUTICALS LTD (IL) 2006-05-31 EP disclosed
WO-2005115492-A1 ABSORBABLE BIOCOMPATIBLE MATERIALS BIOINTERACTIONS LTD (GB) 2005-12-08 WO disclosed
US-20050153369-A1 Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX MILLER JONATHAN L (US) 2005-07-14 US disclosed
EP-1073682-A1 HEPARANASE SPECIFIC MOLECULAR PROBES AND THEIR USE IN RESEARCH AND MEDICAL APPLICATIONS Insight Strategy & Marketing Ltd. (IL) 2001-02-07 EP disclosed
EP-1073682-A4 HEPARANASE SPECIFIC MOLECULAR PROBES AND THEIR USE IN RESEARCH AND MEDICAL APPLICATIONS INSIGHT STRATEGY & MARKETING (IL) 2001-02-07 EP disclosed
WO-1999057153-A1 HEPARANASE SPECIFIC MOLECULAR PROBES AND THEIR USE IN RESEARCH AND MEDICAL APPLICATIONS INSIGHT STRATEGY & MARKETING LTD. (IL) 1999-11-11 WO disclosed
US-5877155-A EXPOSURE OF PLATELETS TO THE MOLECULE (ANTI-MIMOTOPE) IN ORDER TO MODULATE ADHESION, AGGREGATION, OR AGGLUTINATION OF THE PLATELETS. THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1999-03-02 US disclosed
EP-0876396-A1 MIMOTOPES AND ANTI-MIMOTOPES OF HUMAN PLATELET GLYCOPROTEIN Ib/IX THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1998-11-11 EP disclosed
WO-1997018236-A9 MIMOTOPES AND ANTI-MIMOTOPES OF HUMAN PLATELET GLYCOPROTEIN Ib/IX 1997-10-23 WO disclosed
WO-1997018236-A1 MIMOTOPES AND ANTI-MIMOTOPES OF HUMAN PLATELET GLYCOPROTEIN Ib/IX THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1997-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214754-A1 FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF FGFR1, FGF2, FGFR3 AKR1B1 710/4885GPR84 102/4885PPARG 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.